RNA methylation-related genes of m6A, m5C, and m1A predict prognosis and immunotherapy response in cervical cancer

References

• Lin S, Gao K, Gu S, et al. Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years. Cancer. 2021;127(21):4030–4039.
   PubMed Web of Science ®Google Scholar
• Chen T, Wei M, Liu Y, et al. Rising mortality rate of cervical cancer in younger women in urban China. J Gen Intern Med. 2020;35(2):593.
   PubMed Web of Science ®Google Scholar
• He WQ, Li C. Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends. Gynecol Oncol. 2021;163(3):583–592.
   PubMed Web of Science ®Google Scholar
• Barbieri I, Kouzarides T. Role of RNA modifications in cancer. Nat Rev Cancer. 2020;20(6):303–322.
   PubMed Web of Science ®Google Scholar
• Yang H, Wang Y, Xiang Y, et al. Fmrc promotes transcription-coupled homologous recombination via facilitating Tet1-Mediated M5c rna modification demethylation. Proc Natl Acad Sci USA. 2022;119(12):e2116251119.
   PubMed Web of Science ®Google Scholar
• Wu Y, Chen Z, Xie G, et al. Rna M(1)a methylation regulates glycolysis of cancer cells through modulating Atp5d. Proc Natl Acad Sci USA. 2022;119(28):e2119038119.
   PubMed Web of Science ®Google Scholar
• Guan K, Liu X, Li J, et al. Expression status and prognostic value of M6a-associated genes in gastric cancer. J Cancer. 2020;11(10):3027–3040.
   PubMed Web of Science ®Google Scholar
• Wang JZ, Zhu W, Han J, et al. The role of the hif-1alpha/alyref/Pkm2 axis in glycolysis and tumorigenesis of bladder cancer. Cancer Commun. 2021;41(7):560–575.
   Web of Science ®Google Scholar
• Li T, Wang T, Jing J, et al. Expression pattern and clinical value of key M6a RNA modification regulators in abdominal aortic aneurysm. J Inflamm Res. 2021;14:4245–4258.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang J, Su Y, et al. Distinct roles of M(5)C rna methyltransferase Nsun2 in major gynecologic cancers. Front Oncol. 2022;12:786266.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhao Q, Kaboli PJ, et al. M1a regulated genes modulate Pi3k/Akt/mtor and Erbb pathways in gastrointestinal cancer. Transl Oncol. 2019;12(10):1323–1333.
   PubMed Web of Science ®Google Scholar
• Liu R, Shuai Y, Luo J, et al. Sema3c promotes cervical cancer growth and is associated with poor prognosis. Front Oncol. 2019;9:1035.
   PubMed Web of Science ®Google Scholar
• Griesmann H, Muhl S, Riedel J, et al. Cux1 enhances pancreatic cancer formation by synergizing with kras and inducing mek/Erk-dependent proliferation. Cancers. 2021;13(10):2462.
   PubMed Web of Science ®Google Scholar
• Aly M, Ramdzan ZM, Nagata Y, et al. Distinct clinical and biological implications of Cux1 in myeloid neoplasms. Blood Adv. 2019;3(14):2164–2178.
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang H, Chen Z, et al. Carbonic anhydrase 2 inhibits epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma. Carcinogenesis. 2018;39(4):562–570.
   PubMed Web of Science ®Google Scholar
• Xie Q, Li Z, Luo X, et al. Pirna-14633 promotes cervical cancer cell malignancy in a Mettl14-dependent M6a rna methylation manner. J Transl Med. 2022;20(1):51.
   PubMed Web of Science ®Google Scholar
• Lin X, Wang F, Chen J, et al. N(6)-methyladenosine modification of cenpk mrna by Zc3h13 promotes cervical cancer stemness and chemoresistance. Mil Med Res. 2022;9(1):19.
   PubMed Web of Science ®Google Scholar
• Zou J, Li Z, Xie J, et al. Methylation drives Slc2a1 transcription and ferroptosis process decreasing autophagy pressure in colon cancer. J Oncol. 2022;2022:9077424.
   PubMed Web of Science ®Google Scholar
• Reyna-Hernandez MA, Alarcon-Romero LDC, Ortiz-Ortiz J, et al. Glut1, Ldha, and Mct4 expression is deregulated in cervical cancer and precursor lesions. J Histochem Cytochem. 2022;70(6):437–446.
   PubMed Web of Science ®Google Scholar
• Zhang L, Li J, Zhang L. Srsf3 restriction eases cervical cancer cell viability and metastasis via adjusting Pi3k/akt/mtor signaling pathway. Contrast Media Mol Imag. 2022;2022:8497078.
   PubMed Web of Science ®Google Scholar
• Zhen FH, Zhang Y, Yang1 J, et al. MicroRNA-7 inhibits metastasis and invasion through targeting focal adhesion kinase in cervical cancer. Int J Clin Exp Med. 2015;8(1):480–487. www.ijcem.com/ISSN:1940-5901/IJCEM0003395
   PubMed Web of Science ®Google Scholar
• Ma JB, Bai JY, Zhang HB, et al. Downregulation of collagen Col4a6 is associated with prostate cancer progression and metastasis. Genet Test Mol Biomarkers. 2020;24(7):399–408.
   PubMed Web of Science ®Google Scholar
• Heeren AM, Rotman J, Stam AGM, et al. Efficacy of Pd-1 blockade in cervical cancer is related to a Cd8(+)Foxp3(+)Cd25(+) T-cell subset with operational effector functions despite high immune checkpoint levels. J Immunother Cancer. 2019;7(1):43.
   PubMedGoogle Scholar
• Doukuni R, Kobori T, Tanaka C, et al. Moesin serves as scaffold protein for Pd-L1 in human uterine cervical squamous carcinoma cells. JCM. 2022;11(13):3830.
   Google Scholar
• Kagabu M, Nagasawa T, Sato C, et al. Immunotherapy for uterine cervical cancer using checkpoint inhibitors: future directions. Int J Mol Sci. 2020;21(7):2335.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Yuan Y, Chen M, et al. Prmt5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating Pd-L1 expression. Theranostics. 2021;11(18):9162–9176.
   PubMed Web of Science ®Google Scholar
• Tan S, Chen Y, Du S, et al. Tie2-high cervical cancer cells promote tumor angiogenesis by upregulating Tie2 and Vegfr2 in endothelial cells. Transl Oncol. 2022;26:101539.
   PubMed Web of Science ®Google Scholar
• Attademo L, Tuninetti V, Pisano C, et al. Immunotherapy in cervix cancer. Cancer Treat Rev. 2020;90:102088.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Enomoto T, Kast WM, et al. Integration of immunotherapy into treatment of cervical cancer: recent data and ongoing trials. Cancer Treat Rev. 2022;106:102385.
   PubMed Web of Science ®Google Scholar
• Fleischmann M, Chatzikonstantinou G, Fokas E, et al. Molecular markers to predict prognosis and treatment response in uterine cervical cancer. Cancers. 2021;13(22):5748.
   PubMed Web of Science ®Google Scholar
• O’Malley DM, Neffa M, Monk BJ, et al. Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label phase II study. J Clin Oncol. 2022;40(7):762–771.
   PubMed Web of Science ®Google Scholar